Automatic tax sale leaves Dyne Therapeutics (DYN) CEO John Cox with 351,994 direct shares.
Dyne Therapeutics (DYN) CEO John Cox had 5,513 common shares automatically sold on November 13, 2026, at a weighted average price of $16.82 per share. This sale was non-discretionary and intended to satisfy tax-withholding obligations related to restricted stock unit vesting. Following this transaction, Cox directly holds 351,994 shares, including 227,983 unvested RSUs, along with four indirect trust holdings of 18,000 shares each for his children.
Form 4 Dyne Therapeutics Inc: John Cox (Director, CEO & President) For: 13 November By Investing.com
This article reports on a Form 4 filing for Dyne Therapeutics Inc, indicating that John Cox, who serves as Director, CEO, and President, was involved in a transaction on November 13. The brief announcement provides no further details about the nature of the transaction.
Form 4 Dyne Therapeutics Inc: John Cox (Director, CEO & President) For: 13 November
This article reports on a Form 4 filing for Dyne Therapeutics Inc., detailing insider transaction activity for John Cox, who holds positions as Director, CEO, and President. The filing is dated for November 13, without specific details on the nature of the transaction. The stock symbol associated with Dyne Therapeutics Inc. is DYN.
Automatic tax sale: Dyne Therapeutics (DYN) CFO sells shares at $16.82 weighted average.
Dyne Therapeutics (DYN) CFO Erick Lucera sold 1,991 shares of common stock on November 13, 2026, at a weighted-average price of $16.82 per share. This sale was an automatic transaction to cover tax-withholding obligations upon the vesting of restricted stock units and was not a discretionary trade, consistent with Rule 10b5-1. Following the transaction, Lucera's holdings include 117,775 shares, with 102,389 being unvested restricted stock units.
Four Wellington entities report a passive stake above 5% in Dyne Therapeutics (DYN).
Four Wellington entities, including Wellington Management Group LLP and its affiliates, have reported a passive stake in Dyne Therapeutics (DYN) exceeding 5%. According to a Schedule 13G filing, each entity beneficially owns 10,579,924 shares, representing 5.67% of the class as of September 30, 2026. The filing details shared voting and dispositive powers, with the shares owned of record by clients of the Wellington investment advisers.
Officer John Cox proposes selling 5,513 Dyne Therapeutics (DYN) shares around November 13, 2026.
John Cox, an officer at Dyne Therapeutics (DYN), has filed a Form 144 notice proposing to sell 5,513 common shares, valued at approximately $92,751.00, with an anticipated sale date of November 13, 2026. This proposed sale follows a previous sale of 5,658 common shares on September 8, 2026, which yielded gross proceeds of $106,844.00. Additionally, Cox acquired 11,250 restricted stock units from the issuer as equity compensation on November 13, 2026.
Officer Doug Kerr proposes selling 2,604 shares of Dyne Therapeutics (DYN).
Dyne Therapeutics officer Doug Kerr has reported a proposed sale of 2,604 common shares, valued at approximately $43,810, with an approximate sale date of November 13, 2026. This Form 144 filing also details prior sales made by Kerr in September 2026 and the acquisition of 5,312 restricted stock units from the issuer on November 13, 2026, as equity compensation. The filing indicates the sale will be facilitated by Stifel Nicolaus & Company Inc. and traded on Nasdaq.
Dyne Therapeutics to Participate in Upcoming Investor Conference
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced its participation in the Jefferies Global Healthcare Conference on November 16, 2026, where management will hold a fireside chat. A live webcast of the event will be available on Dyne’s website, with a replay accessible for 90 days. The company focuses on developing therapeutics for genetically driven neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy type 1.
Dyne Therapeutics to Participate in Upcoming Investor Conference
Dyne Therapeutics (Nasdaq: DYN) announced its management will participate in the Jefferies Global Healthcare Conference on November 16, 2026, for a fireside chat in London. The clinical-stage company focuses on developing therapeutics for genetically driven neuromuscular diseases, with programs for Duchenne muscular dystrophy and myotonic dystrophy type 1. A live webcast and replay of the event will be available on Dyne’s investor relations website.
PepGen Shares Double as Muscle Drug Posts Record Splicing Correction
PepGen Ltd shares more than doubled after its Phase 2 DM1 drug, PGN-EDODM1, achieved a record 46.5% mean muscle splicing correction, significantly outperforming placebo. The drug also showed functional gains in hand opening time and grip strength with a favorable safety profile. Analysts view these results as a potential new benchmark for myotonic dystrophy type 1 treatment, surpassing rival candidates.
PepGen reports 46.5% splicing correction in DM1 trial
PepGen Inc. reported positive Phase 2 results for its DM1 trial, showing an average of 46.5% splicing correction in six treated patients and functional improvements in hand opening and grip strength. The company maintains a strong cash position but faces a partial FDA clinical hold, which needs to be resolved before an end-of-Phase 2 meeting can occur in the second half of 2027. Further extension data is expected in January 2027.
Why Dyne Therapeutics Stock Is In Focus After Wider Quarterly Losses
Dyne Therapeutics reported wider net losses in Q3 2026 and for the first nine months of the year, driven by high R&D costs for its late-stage neuromuscular programs. Despite these losses, the company's investment narrative centers on the potential of its FORCE platform and lead programs, with key upcoming catalysts including an FDA priority review for z rostudirsen and topline data for z basivarsen in early 2027. The increased losses underscore the importance of funding discipline, dilution risk, and the eventual commercial efficiency required to translate pipeline success into product sales.
Can Dyne Therapeutics (DYN) Justify Its Valuation Following A Wider Loss And FDA Review?
Dyne Therapeutics (DYN) recently reported a wider third-quarter net loss and provided an update on the FDA's priority review for its Duchenne muscular dystrophy drug candidate. This has drawn attention to the company's cash burn and regulatory timelines. Despite short-term stock volatility, including a recent rebound, the long-term shareholder return remains positive.
Form 8K Dyne Therapeutics Inc For: 5 November By Investing.com
This article announces that Dyne Therapeutics Inc. filed a Form 8K on November 5. The brief report from Investing.com indicates that the filing is relevant to the stock market, with Dyne Therapeutics' stock symbol DYN mentioned. No further details about the content of the 8K filing are provided.
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics announced its Q3 2026 financial results and key business advancements, including the FDA's priority review of its BLA for z-rostudirsen in exon 51 DMD with a PDUFA target date of January 21, 2027. The company also reported positive one-year clinical data for z-basivarsen in DM1 from the Phase 1/2 ACHIEVE trial, with topline data from the registrational expansion cohort expected in Q1 2027. Dyne's cash position was $1.134 billion as of September 30, 2026, projected to fund operations into Q2 2028.
Dyne Therapeutics, Inc. (DYN) Seasonal returns chart - Yahoo Finance
This article from Yahoo Finance provides a seasonal returns chart for Dyne Therapeutics, Inc. (DYN). It displays the average monthly price return for the company's stock from 2020 to 2026. The page also includes current stock information, related tickers, and market data for various global indices and cryptocurrencies.
Precision Trading with Dyne Therapeutics Inc. (DYN) Risk Zones
This article provides an in-depth analysis of Dyne Therapeutics Inc. (DYN), highlighting a strong near and mid-term sentiment that could extend long-term. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, emphasizing support and resistance levels for different holding periods.
Dyne Therapeutics, Inc. (DYN) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Dyne Therapeutics, Inc. (DYN), showing average monthly price returns from 2020 to 2026. It indicates that the stock closed at $17.30, up 3.65% in regular trading, with no change in after-hours trading. The page also includes various market data and navigation options for Yahoo Finance.
Dyne Therapeutics, Inc. (DYN) Seasonal returns chart
This Yahoo Finance article presents a seasonal returns chart for Dyne Therapeutics, Inc. (DYN), displaying the average monthly price return from 2020 to 2026. The stock was trading at $17.30, up 3.65% at market close on November 2nd. The page provides quick access to various financial data points for DYN.
Form 4 Dyne Therapeutics Inc: Douglas Kerr (Head of R&D and CMO) For: 20 October By Investing.com
This article reports on a Form 4 filing for Dyne Therapeutics Inc, specifically detailing a transaction by Douglas Kerr, who holds the positions of Head of R&D and CMO. The filing pertains to activity on October 20. The article also includes the company's stock symbol, DYN, and its current price performance.
Form 4 Dyne Therapeutics Inc: Douglas Kerr (Head of R&D and CMO) For: 20 October
This article reports on a Form 4 filing for Dyne Therapeutics Inc., specifically detailing a transaction or report involving Douglas Kerr, the company's Head of R&D and CMO, for October 20. The filing indicates insider activity related to the company's stock, DYN.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced inducement equity awards granted to 16 newly hired employees. These awards, consisting of non-statutory stock options for 290,100 shares and restricted stock units for 92,300 shares, were made in accordance with Nasdaq Listing Rule 5635(c)(4) to induce their employment. The awards have vesting schedules over four years, contingent on continued service to the company.
Dyne Therapeutics, Inc. Estimates – NASDAQ:DYN
This article focuses on the financial estimates for Dyne Therapeutics, Inc. (NASDAQ:DYN) available on TradingView. It highlights where users can explore reported financial data and analyst estimates, including income statements, balance sheets, and cash flow statements, and compare actual results with average, high, and low estimates. The platform also allows visualization of financial trends over time.
Form 4 Dyne Therapeutics Inc: Douglas Kerr (Head of R&D and CMO) For: 20 October
This article reports on a Form 4 filing for Dyne Therapeutics Inc, specifically detailing transactions by Douglas Kerr, the Head of R&D and CMO. The filing pertains to activities that occurred on October 20th. The brief announcement indicates a disclosure of insider transactions for the company.
A 12,000-share option goes to Dyne Therapeutics (DYN) CMO Douglas Kerr alongside a stock award.
Dyne Therapeutics (DYN) announced that its Head of R&D and CMO, Douglas Kerr, received an award of 8,000 restricted stock units (RSUs) and a stock option for 12,000 shares on October 20, 2026. The RSUs will vest quarterly over four years starting January 20, 2027, and the option shares will vest monthly through October 20, 2030, with an exercise price of $16.27 per share. Following these awards, Kerr's reported common-stock holdings, including unvested RSUs, total 170,564 shares.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced it has granted inducement equity awards to 16 new employees, consisting of non-statutory stock options for up to 290,100 shares and restricted stock units for 92,300 shares. These awards were made to induce their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and restricted stock units are subject to four-year vesting schedules and the terms of Dyne's 2024 Inducement Stock Incentive Plan.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics, Inc. announced it has granted inducement equity awards to 16 new employees, consisting of non-statutory stock options for up to 290,100 shares and restricted stock units for 92,300 shares. These awards were made to induce their employment, in accordance with Nasdaq Listing Rule 5635(c)(4), with vesting schedules over four years subject to continued service. The company is a clinical-stage firm focused on treating genetically driven neuromuscular diseases.
Form 4 Dyne Therapeutics Inc: Douglas Kerr (Head of R&D and CMO) For: 20 October
This article reports on a Form 4 filing for Dyne Therapeutics Inc, specifically detailing transactions by Douglas Kerr, who serves as the Head of R&D and CMO. The filing is dated for October 20. The article, published by Investing.com, provides only the headline information without further details on the nature of the transactions.
Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?
Dyne Therapeutics reported positive one-year data from its Phase 1/2 ACHIEVE trial for z basivarsen in DM1, showing sustained improvements and a favorable safety profile. This data supports the company's investment narrative, which includes the potential for significant revenue and profit growth by 2029 if its pipeline clears regulatory hurdles, especially with upcoming catalysts for DM1 and DMD treatments. However, the company faces high R&D costs, potential shareholder dilution, and demanding valuation assumptions based on these future successes.
Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?
Dyne Therapeutics has released positive one-year data from its Phase 1/2 ACHIEVE trial for z basivarsen in DM1, showing sustained improvements. This supports the company's investment thesis, although significant risks remain with upcoming regulatory readouts. The long-term forecast anticipates substantial revenue and profit growth by 2029, reflecting high expectations for its pipeline success, especially in DM1 and DMD, which is already embedded in its demanding valuation multiples.
How (DYN) Movements Inform Risk Allocation Models
This article analyzes Dyne Therapeutics Inc. (NYSE: DYN) movements, noting positive near-term sentiment amidst a weak mid-term and strong long-term context. It highlights elevated downside risk and provides AI-generated institutional trading strategies for different risk profiles. The strategies include position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Dyne Therapeutics (DYN) After Fresh ACHIEVE Data With Undervalued Narrative Intact
Dyne Therapeutics (DYN) has released new one-year results from its Phase 1/2 ACHIEVE trial for DYNE-101 in myotonic dystrophy type 1, showing sustained functional gains. Despite a recent share price decline, the company is considered significantly undervalued by Simply Wall St, with a fair value estimate of $36.0 against a last close of $15.40. The upcoming PDUFA date for z-rostudirsen in January 2027 provides a potential path to revenue generation, though risks like trial failures or equity dilution remain.
At $16 a share, director Brian S. Posner buys 2,500 Dyne Therapeutics (DYN) shares.
Dyne Therapeutics director Brian S. Posner purchased 2,500 shares of the company's common stock at $16 per share on October 2, 2026. This transaction increased his direct holdings to 27,000 shares. No Rule 10b5-1 plan was reported for this purchase, and the filing is considered neutral in impact with positive sentiment.
Does One Year DM1 Trial Data Change The Bull Case For Dyne Therapeutics Stock?
Dyne Therapeutics released positive one-year data from its Phase 1/2 ACHIEVE trial for zeleciment basivarsen in DM1, showing sustained functional and strength improvements with a favorable safety profile. This data directly links to their Phase 3 registrational plans, focusing on specific functional endpoints for potential accelerated and traditional approvals, thereby concentrating future regulatory and execution risk. The report suggests this clinical momentum and valuation upside are critical for Dyne's investment narrative, particularly given its pre-commercial stage and significant annual loss.
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40
LifeSci Capital has reiterated its Buy rating for Dyne Therapeutics (DYN.US) and maintained its target price at $40. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.
Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)
Analysts from Warburg Research and Deutsche Bank maintained a Buy rating for Medios AG, with price targets of EUR20.00 and EUR16.00 respectively, projecting a significant upside from current levels. Similarly, Stifel Nicolaus and Raymond James reiterated Buy ratings for Dyne Therapeutics, setting a price target of $37.00 and expecting a substantial upside. Both companies received a "Strong Buy" analyst consensus rating.
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) after the biotech company released additional one-year data from its Phase 1/2 ACHIEVE study for DM1 patients. Despite a 17% year-to-date stock decline, shares are up 28% over the past year. The company's financial position is strong, with more cash than debt, as it progresses towards regulatory milestones, though some analysts have adjusted price targets due to Novartis's recent trial failure in a similar study.
Dyne Therapeutics, Inc. (DYN) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Dyne Therapeutics, Inc. (DYN) stock, including its current price, after-hours trading, and key historical data. The page displays the stock's performance range, volume, market capitalization, and various financial metrics. It also offers sections for news, charts, community discussions, and detailed financial analysis.
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
This article states that Chardan Capital has maintained its "Buy" rating for Dyne Therapeutics. No further details about the company, the analyst's rationale, or financial data are provided in the current content.
Dyne Therapeutics (NasdaqGS:DYN) Stock Forecast & Analyst Predictions
Dyne Therapeutics (DYN) is forecast to grow earnings by 27.8% and revenue by 64.1% annually, with EPS projected to increase by 31.5% per year, though it is expected to remain unprofitable for the next three years. Analyst price targets have fluctuated, with recent updates decreasing targets, and the company is actively advancing its pipeline with clinical trials for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) therapies. Recent announcements highlight FDA approvals, clinical data, and financing activities, alongside risks like shareholder dilution and persistent unprofitability.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Inc (NASDAQ:DYN) shares increased by 2.1% after reporting positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The Phase 1/2 ACHIEVE trial showed functional improvements across multiple measures at 12 months, including a significant decrease in video hand opening time. The company anticipates topline data in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
DYN Maintained by Chardan Capital -- Price Target Holds at $38
Chardan Capital has maintained a "Buy" rating for Dyne Therapeutics (DYN) with a price target of $38.00, suggesting the stock is currently undervalued compared to its market price of $16.21. Dyne Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing therapies for genetically driven neuromuscular diseases, but faces challenges with profitability and substantial insider selling. The company's GF Score is 40/100, indicating mixed financial health with strong momentum but weak profitability.
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target
Chardan Capital has reiterated its Buy rating on Dyne Therapeutics (DYN) and set a price target of $38.00, representing a significant upside of 134.4% from its recent closing price. The positive outlook is attributed to promising clinical data showing improvements in muscle function and a valuable pipeline with potential for market exclusivity through orphan drug designations.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics (NASDAQ:DYN) shares rose 2.1% in after-hours trading after releasing positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The clinical-stage biotechnology company reported functional improvements in patients, including decreased video hand opening time and improvements in sit-to-stand and walk/run tests. The company expects further topline data in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data?
Dyne Therapeutics (DYN) recently released positive one-year efficacy data from its ACHIEVE trial for myotonic dystrophy type 1, showing sustained functional gains and a clean safety profile. Despite this clinical success, the company's share price has seen a significant short-term pullback. The article discusses whether this pullback presents a buying opportunity or reflects concerns about the drug platform's valuation, cash burn, and execution risks for future product launches.
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics announced additional one-year efficacy data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1 (DM1), showing functional improvements in walking, muscle strength, and patient-reported outcomes. The pooled data, presented at medical conferences, demonstrated sustained benefits compared to baseline, placebo, and natural history cohorts, with a favorable safety profile. Dyne anticipates registrational expansion cohort topline data in Q1 2027, aiming for a potential U.S. Accelerated Approval application in Q3 2027.
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics announced additional one-year efficacy data from its Phase 1/2 ACHIEVE clinical trial of z-basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1), showing functional improvement across multiple measures. The data, presented at the World Muscle Society and AANEM meetings, indicated sustained improvements in myotonia, function, strength, and patient-reported outcomes compared to baseline, placebo, and matched natural history cohorts. Dyne expects topline data from the ACHIEVE registrational expansion cohort in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Inc. (NASDAQ:DYN) shares rose after reporting positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The Phase 1/2 ACHIEVE trial showed functional improvements at 12 months, including decreased video hand opening time and improvements in sit-to-stand and walk/run tests. The company anticipates topline data in Q1 2027 to support a potential U.S. Accelerated Approval submission in Q3 2027.
Dyne Therapeutics stock rises on positive DM1 trial results
Dyne Therapeutics Inc. (NASDAQ: DYN) shares rose after reporting positive one-year trial data for its experimental DM1 treatment, z-basivarsen. The Phase 1/2 ACHIEVE trial showed functional improvements, including decreases in video hand opening time and improvements in muscle strength. The company expects topline data from the registrational expansion cohort in Q1 2027, aiming for a U.S. Accelerated Approval submission in Q3 2027.
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence
Piper Sandler has reiterated an Overweight rating and a $47.00 price target for Dyne Therapeutics (NASDAQ:DYN), expressing confidence in the accelerated approval of Zeleciment rostudirsen for DMD boys by the January 21 PDUFA date. Despite a year-to-date stock decline of 16.46%, the company's financial health is strong, holding more cash than debt and a current ratio of 12.02. Upcoming presentations of 1-year Phase I Zeleciment basivarsen data are anticipated, while recent analyst updates show a mixed but cautiously optimistic outlook for Dyne Therapeutics.